Share Price and Basic Stock Data
Last Updated: December 13, 2025, 3:21 am
| PEG Ratio | 0.26 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Entero Healthcare Solutions Ltd operates in the pharmaceuticals sector, focusing on providing healthcare solutions and products. As of September 2023, the company’s share price stood at ₹996, with a market capitalization of ₹4,334 Cr. Over the past few quarters, Entero has demonstrated a consistent upward trajectory in its sales, which rose from ₹829 Cr in December 2022 to ₹996 Cr by September 2023. This growth reflects a robust demand for its offerings, with sales projected to reach ₹1,034 Cr in March 2024. The revenue growth is a positive signal for investors, indicating that the company is effectively capitalizing on market opportunities, particularly considering the pharmaceutical industry’s resilience during economic fluctuations. However, the company’s operating profit margin (OPM) remains relatively low at 4%, suggesting that while sales are increasing, the efficiency with which these sales translate into profit could be improved.
Profitability and Efficiency Metrics
Profitability metrics for Entero Healthcare Solutions present a mixed picture. The company recorded a net profit of ₹117 Cr for the trailing twelve months (TTM), with a net profit margin of 2.1%. While this is an improvement from previous years, where the company faced net losses, the current return on equity (ROE) stands at just 5.63%, which is below the expected benchmarks for the sector. The operating profit increased significantly from ₹64 Cr in March 2023 to ₹112 Cr in March 2024, indicating a positive trend. However, the operating profit margin has not shown corresponding growth, remaining stagnant at around 3% to 4%. This suggests that while Entero is expanding its revenue base, it needs to focus on controlling costs to enhance profitability further. The interest coverage ratio of 5.07x provides some comfort, indicating that the company can comfortably meet its interest obligations, but the overall efficiency ratios, such as return on capital employed (ROCE) at 8.71%, point towards room for improvement.
Balance Sheet Strength and Financial Ratios
The balance sheet of Entero Healthcare Solutions reflects a cautious approach to capital management. With total borrowings of ₹443 Cr against reserves of ₹1,723 Cr, the company appears to maintain a healthy reserve position, allowing for financial stability. The current ratio of 2.46x indicates that Entero is well-positioned to cover its short-term liabilities, contributing to a sense of financial security for investors. However, the total debt to equity ratio stands at 0.17, which, while manageable, suggests that the company has opted for a conservative leverage strategy. This could limit growth opportunities if the company is too cautious in pursuing debt for expansion. Moreover, the price-to-book value (P/BV) ratio of 2.87x indicates that the market values the company at a premium compared to its book value, reflecting investor confidence but also potentially signaling overvaluation in a market correction scenario.
Shareholding Pattern and Investor Confidence
Investor confidence in Entero Healthcare Solutions is evidenced by its shareholding pattern. Promoters hold a significant stake of 52.42%, which suggests a strong commitment to the company’s long-term growth. However, the decreasing foreign institutional investor (FII) stake from 23.30% in March 2024 to 14.68% in September 2025 could raise concerns regarding external confidence in the company’s prospects. Domestic institutional investors (DIIs) have also shown a modest but stable interest, holding around 9.64% of the shares. The public stake has increased to 23.26%, indicating growing retail interest. The total number of shareholders is around 36,334, reflecting a diverse ownership base. This situation highlights a blend of stability from promoters and potential volatility from institutional investors, suggesting that while the company has a solid foundation, ongoing monitoring of investor sentiment will be crucial for sustaining growth.
Outlook, Risks, and Final Insight
Looking ahead, Entero Healthcare Solutions presents a mixed outlook. On the one hand, the consistent revenue growth and improving profitability metrics are encouraging signs for potential investors. However, the company faces significant challenges, including the need to enhance its operating margins and manage its cost structure effectively. The pharmaceutical sector is inherently competitive, and Entero must navigate pricing pressures and regulatory hurdles. Additionally, the decline in FII participation may signal caution among institutional investors regarding the company’s long-term growth strategy. For retail investors, vigilance is essential; monitoring the company’s ability to improve profitability while maintaining a strong balance sheet will be key. Overall, while Entero Healthcare Solutions shows promise, potential investors should weigh these strengths against the inherent risks in the sector and the company’s current operational efficiency.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 237/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,250 Cr. | 390 | 479/192 | 88.0 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.1 Cr. | 44.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.1 | 31.0/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,476.95 Cr | 1,156.03 | 52.77 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 829 | 887 | 899 | 996 | 993 | 1,034 | 1,097 | 1,301 | 1,359 | 1,339 | 1,404 |
| Expenses | 810 | 867 | 873 | 968 | 964 | 1,005 | 1,067 | 1,258 | 1,309 | 1,290 | 1,354 |
| Operating Profit | 19 | 20 | 26 | 29 | 29 | 29 | 30 | 42 | 50 | 49 | 50 |
| OPM % | 2% | 2% | 3% | 3% | 3% | 3% | 3% | 3% | 4% | 4% | 4% |
| Other Income | 2 | 1 | 1 | 2 | 2 | 9 | 13 | 11 | 8 | 7 | 6 |
| Interest | 13 | 13 | 14 | 18 | 16 | 17 | 10 | 11 | 10 | 10 | 11 |
| Depreciation | 5 | 7 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 9 |
| Profit before tax | 2 | 1 | 7 | 7 | 8 | 14 | 27 | 35 | 39 | 37 | 36 |
| Tax % | -44% | 490% | 6% | 23% | 16% | -56% | 25% | 25% | 25% | 16% | 17% |
| Net Profit | 4 | -4 | 6 | 5 | 7 | 21 | 21 | 26 | 29 | 31 | 30 |
| EPS in Rs | 8.05 | -9.05 | 15.18 | 3.19 | 4.22 | 4.82 | 4.62 | 5.43 | 5.85 | 5.91 | 6.39 |
Last Updated: August 19, 2025, 3:47 pm
Below is a detailed analysis of the quarterly data for Entero Healthcare Solutions Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,404.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,339.00 Cr. (Mar 2025) to 1,404.00 Cr., marking an increase of 65.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,354.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,290.00 Cr. (Mar 2025) to 1,354.00 Cr., marking an increase of 64.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 49.00 Cr. (Mar 2025) to 50.00 Cr., marking an increase of 1.00 Cr..
- For OPM %, as of Jun 2025, the value is 4.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00%.
- For Other Income, as of Jun 2025, the value is 6.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7.00 Cr. (Mar 2025) to 6.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 11.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 9.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 36.00 Cr.. The value appears to be declining and may need further review. It has decreased from 37.00 Cr. (Mar 2025) to 36.00 Cr., marking a decrease of 1.00 Cr..
- For Tax %, as of Jun 2025, the value is 17.00%. The value appears to be increasing, which may not be favorable. It has increased from 16.00% (Mar 2025) to 17.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 30.00 Cr.. The value appears to be declining and may need further review. It has decreased from 31.00 Cr. (Mar 2025) to 30.00 Cr., marking a decrease of 1.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 6.39. The value appears strong and on an upward trend. It has increased from 5.91 (Mar 2025) to 6.39, marking an increase of 0.48.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:24 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 1,350 | 1,773 | 2,522 | 3,300 | 3,922 | 5,096 | 5,403 |
| Expenses | 1,326 | 1,758 | 2,498 | 3,236 | 3,810 | 4,924 | 5,211 |
| Operating Profit | 23 | 15 | 24 | 64 | 112 | 172 | 191 |
| OPM % | 2% | 1% | 1% | 2% | 3% | 3% | 4% |
| Other Income | 5 | 11 | 4 | 6 | 14 | 39 | 32 |
| Interest | 13 | 20 | 29 | 49 | 66 | 42 | 43 |
| Depreciation | 12 | 16 | 20 | 24 | 25 | 31 | 33 |
| Profit before tax | 4 | -11 | -20 | -4 | 36 | 139 | 148 |
| Tax % | 67% | 42% | 49% | 201% | -12% | 23% | |
| Net Profit | 1 | -15 | -29 | -11 | 40 | 107 | 117 |
| EPS in Rs | 93.81 | -1,550.90 | -77.71 | -28.12 | 8.99 | 21.80 | 23.58 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -1600.00% | -93.33% | 62.07% | 463.64% | 167.50% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1506.67% | 155.40% | 401.57% | -296.14% |
Entero Healthcare Solutions Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 26% |
| TTM: | 31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 152% |
| 3 Years: | 73% |
| TTM: | 94% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -17% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 6% |
Last Updated: September 5, 2025, 3:26 pm
Balance Sheet
Last Updated: December 10, 2025, 4:15 am
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.10 | 0.10 | 4 | 4 | 43 | 44 | 44 |
| Reserves | -16 | -32 | -62 | -73 | 1,595 | 1,681 | 1,723 |
| Borrowings | 603 | 720 | 974 | 1,101 | 338 | 385 | 443 |
| Other Liabilities | 162 | 147 | 210 | 275 | 369 | 593 | 642 |
| Total Liabilities | 749 | 836 | 1,125 | 1,308 | 2,345 | 2,703 | 2,851 |
| Fixed Assets | 186 | 189 | 262 | 268 | 289 | 559 | 627 |
| CWIP | 2 | 2 | 1 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 58 | 67 |
| Other Assets | 560 | 645 | 863 | 1,040 | 2,056 | 2,085 | 2,158 |
| Total Assets | 749 | 836 | 1,125 | 1,308 | 2,345 | 2,703 | 2,851 |
Below is a detailed analysis of the balance sheet data for Entero Healthcare Solutions Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 44.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 44.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,723.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,681.00 Cr. (Mar 2025) to 1,723.00 Cr., marking an increase of 42.00 Cr..
- For Borrowings, as of Sep 2025, the value is 443.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 385.00 Cr. (Mar 2025) to 443.00 Cr., marking an increase of 58.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 642.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 593.00 Cr. (Mar 2025) to 642.00 Cr., marking an increase of 49.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,851.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,703.00 Cr. (Mar 2025) to 2,851.00 Cr., marking an increase of 148.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 627.00 Cr.. The value appears strong and on an upward trend. It has increased from 559.00 Cr. (Mar 2025) to 627.00 Cr., marking an increase of 68.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 67.00 Cr.. The value appears strong and on an upward trend. It has increased from 58.00 Cr. (Mar 2025) to 67.00 Cr., marking an increase of 9.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,158.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,085.00 Cr. (Mar 2025) to 2,158.00 Cr., marking an increase of 73.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,851.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,703.00 Cr. (Mar 2025) to 2,851.00 Cr., marking an increase of 148.00 Cr..
Notably, the Reserves (1,723.00 Cr.) exceed the Borrowings (443.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Free Cash Flow | -580.00 | -705.00 | -950.00 | 63.00 | -226.00 | -213.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 63 | 50 | 54 | 57 | 57 | 59 |
| Inventory Days | 57 | 54 | 49 | 41 | 43 | 52 |
| Days Payable | 32 | 22 | 22 | 25 | 24 | 31 |
| Cash Conversion Cycle | 88 | 82 | 81 | 73 | 77 | 80 |
| Working Capital Days | 57 | 54 | 41 | 32 | 48 | 65 |
| ROCE % | 1% | 1% | 5% | 7% | 9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Invesco India Contra Fund | 1,577,379 | 0.86 | 174.36 | N/A | N/A | N/A |
| Invesco India ELSS Tax Saver Fund | 450,000 | 1.74 | 49.74 | N/A | N/A | N/A |
| Invesco India Aggressive Hybrid Fund | 30,000 | 0.41 | 3.32 | N/A | N/A | N/A |
| HSBC Tax Saver Equity Fund | 21,400 | 0.96 | 2.37 | N/A | N/A | N/A |
| Invesco India Equity Savings Fund | 17,000 | 0.43 | 1.88 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 21.80 | 10.81 | -3.10 | -9.22 | -5.29 |
| Diluted EPS (Rs.) | 21.76 | 10.81 | -3.10 | -9.22 | -5.29 |
| Cash EPS (Rs.) | 31.75 | 14.90 | 31.94 | -25.16 | 92.20 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 396.28 | 377.38 | -160.39 | -144.87 | -3005.20 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 396.28 | 377.38 | -160.39 | -144.87 | -3005.20 |
| Revenue From Operations / Share (Rs.) | 1171.23 | 901.80 | 8025.80 | 6550.82 | 177973.70 |
| PBDIT / Share (Rs.) | 48.51 | 29.03 | 169.07 | 75.12 | 2547.60 |
| PBIT / Share (Rs.) | 41.45 | 23.28 | 110.13 | 23.81 | 920.00 |
| PBT / Share (Rs.) | 31.89 | 8.17 | -8.97 | -51.46 | -1083.80 |
| Net Profit / Share (Rs.) | 24.69 | 9.15 | -27.00 | -76.46 | -1535.40 |
| NP After MI And SOA / Share (Rs.) | 21.79 | 8.99 | -28.11 | -77.71 | -1553.70 |
| PBDIT Margin (%) | 4.14 | 3.21 | 2.10 | 1.14 | 1.43 |
| PBIT Margin (%) | 3.53 | 2.58 | 1.37 | 0.36 | 0.51 |
| PBT Margin (%) | 2.72 | 0.90 | -0.11 | -0.78 | -0.60 |
| Net Profit Margin (%) | 2.10 | 1.01 | -0.33 | -1.16 | -0.86 |
| NP After MI And SOA Margin (%) | 1.86 | 0.99 | -0.35 | -1.18 | -0.87 |
| Return on Networth / Equity (%) | 5.49 | 2.38 | 0.00 | 0.00 | 0.00 |
| Return on Capital Employeed (%) | 9.70 | 5.80 | 6.61 | 1.38 | 1.68 |
| Return On Assets (%) | 3.50 | 1.66 | -0.88 | -2.65 | -1.86 |
| Long Term Debt / Equity (X) | 0.00 | 0.02 | -0.45 | -0.64 | 0.00 |
| Total Debt / Equity (X) | 0.17 | 0.16 | -5.45 | -4.92 | -4.46 |
| Asset Turnover Ratio (%) | 2.02 | 2.15 | 2.71 | 2.57 | 0.00 |
| Current Ratio (X) | 2.46 | 3.34 | 1.64 | 1.84 | 2.19 |
| Quick Ratio (X) | 1.68 | 2.64 | 1.09 | 1.17 | 1.35 |
| Inventory Turnover Ratio (X) | 9.43 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 5.07 | 1.92 | 1.42 | 0.99 | 1.27 |
| Interest Coverage Ratio (Post Tax) (X) | 3.58 | 1.61 | 0.77 | -0.01 | 0.23 |
| Enterprise Value (Cr.) | 5029.50 | 3669.42 | 0.00 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 0.98 | 0.93 | 0.00 | 0.00 | 0.00 |
| EV / EBITDA (X) | 23.83 | 29.06 | 0.00 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.97 | 1.09 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 2.87 | 2.62 | 0.00 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 0.97 | 1.09 | 0.00 | 0.00 | 0.00 |
| EarningsYield | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
After reviewing the key financial ratios for Entero Healthcare Solutions Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 21.80. This value is within the healthy range. It has increased from 10.81 (Mar 24) to 21.80, marking an increase of 10.99.
- For Diluted EPS (Rs.), as of Mar 25, the value is 21.76. This value is within the healthy range. It has increased from 10.81 (Mar 24) to 21.76, marking an increase of 10.95.
- For Cash EPS (Rs.), as of Mar 25, the value is 31.75. This value is within the healthy range. It has increased from 14.90 (Mar 24) to 31.75, marking an increase of 16.85.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 396.28. It has increased from 377.38 (Mar 24) to 396.28, marking an increase of 18.90.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 396.28. It has increased from 377.38 (Mar 24) to 396.28, marking an increase of 18.90.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,171.23. It has increased from 901.80 (Mar 24) to 1,171.23, marking an increase of 269.43.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 48.51. This value is within the healthy range. It has increased from 29.03 (Mar 24) to 48.51, marking an increase of 19.48.
- For PBIT / Share (Rs.), as of Mar 25, the value is 41.45. This value is within the healthy range. It has increased from 23.28 (Mar 24) to 41.45, marking an increase of 18.17.
- For PBT / Share (Rs.), as of Mar 25, the value is 31.89. This value is within the healthy range. It has increased from 8.17 (Mar 24) to 31.89, marking an increase of 23.72.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 24.69. This value is within the healthy range. It has increased from 9.15 (Mar 24) to 24.69, marking an increase of 15.54.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 21.79. This value is within the healthy range. It has increased from 8.99 (Mar 24) to 21.79, marking an increase of 12.80.
- For PBDIT Margin (%), as of Mar 25, the value is 4.14. This value is below the healthy minimum of 10. It has increased from 3.21 (Mar 24) to 4.14, marking an increase of 0.93.
- For PBIT Margin (%), as of Mar 25, the value is 3.53. This value is below the healthy minimum of 10. It has increased from 2.58 (Mar 24) to 3.53, marking an increase of 0.95.
- For PBT Margin (%), as of Mar 25, the value is 2.72. This value is below the healthy minimum of 10. It has increased from 0.90 (Mar 24) to 2.72, marking an increase of 1.82.
- For Net Profit Margin (%), as of Mar 25, the value is 2.10. This value is below the healthy minimum of 5. It has increased from 1.01 (Mar 24) to 2.10, marking an increase of 1.09.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.86. This value is below the healthy minimum of 8. It has increased from 0.99 (Mar 24) to 1.86, marking an increase of 0.87.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.49. This value is below the healthy minimum of 15. It has increased from 2.38 (Mar 24) to 5.49, marking an increase of 3.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.70. This value is below the healthy minimum of 10. It has increased from 5.80 (Mar 24) to 9.70, marking an increase of 3.90.
- For Return On Assets (%), as of Mar 25, the value is 3.50. This value is below the healthy minimum of 5. It has increased from 1.66 (Mar 24) to 3.50, marking an increase of 1.84.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has increased from 0.16 (Mar 24) to 0.17, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 2.02. It has decreased from 2.15 (Mar 24) to 2.02, marking a decrease of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 2.46. This value is within the healthy range. It has decreased from 3.34 (Mar 24) to 2.46, marking a decrease of 0.88.
- For Quick Ratio (X), as of Mar 25, the value is 1.68. This value is within the healthy range. It has decreased from 2.64 (Mar 24) to 1.68, marking a decrease of 0.96.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.43. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 9.43, marking an increase of 9.43.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.07. This value is within the healthy range. It has increased from 1.92 (Mar 24) to 5.07, marking an increase of 3.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.58. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 3.58, marking an increase of 1.97.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,029.50. It has increased from 3,669.42 (Mar 24) to 5,029.50, marking an increase of 1,360.08.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1. It has increased from 0.93 (Mar 24) to 0.98, marking an increase of 0.05.
- For EV / EBITDA (X), as of Mar 25, the value is 23.83. This value exceeds the healthy maximum of 15. It has decreased from 29.06 (Mar 24) to 23.83, marking a decrease of 5.23.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. It has decreased from 1.09 (Mar 24) to 0.97, marking a decrease of 0.12.
- For Price / BV (X), as of Mar 25, the value is 2.87. This value is within the healthy range. It has increased from 2.62 (Mar 24) to 2.87, marking an increase of 0.25.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. It has decreased from 1.09 (Mar 24) to 0.97, marking a decrease of 0.12.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Entero Healthcare Solutions Ltd:
- Net Profit Margin: 2.1%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.7% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.49% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.58
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.68
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 39.2 (Industry average Stock P/E: 52.77)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.17
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.1%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No. I-35, Building - B, Industrial Area, Phase - I, Faridabad Haryana 121003 | info@enterohealthcare.com http://www.enterohealthcare.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sujesh Vasudevan | Chairperson (NonExe.&Ind.Director) |
| Mr. Prabhat Agrawal | Managing Director & CEO |
| Mr. Prem Sethi | Whole Time Director & COO |
| Mr. Rajesh Shashikant Dalal | Ind. Non-Executive Director |
| Ms. Sandhya Gadkari Sharma | Ind. Non-Executive Director |
| Mr. Arun Sadhanandham | Non Exe.Non Ind.Director |
| Ms. Sumona Chakraborty | Non Exe.Non Ind.Director |
| Mr. Kevin Rohitbhai Daftary | Non Exe.Non Ind.Director |
FAQ
What is the intrinsic value of Entero Healthcare Solutions Ltd?
Entero Healthcare Solutions Ltd's intrinsic value (as of 13 December 2025) is 731.16 which is 26.59% lower the current market price of 996.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4,335 Cr. market cap, FY2025-2026 high/low of 1,565/978, reserves of ₹1,723 Cr, and liabilities of 2,851 Cr.
What is the Market Cap of Entero Healthcare Solutions Ltd?
The Market Cap of Entero Healthcare Solutions Ltd is 4,335 Cr..
What is the current Stock Price of Entero Healthcare Solutions Ltd as on 13 December 2025?
The current stock price of Entero Healthcare Solutions Ltd as on 13 December 2025 is 996.
What is the High / Low of Entero Healthcare Solutions Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Entero Healthcare Solutions Ltd stocks is 1,565/978.
What is the Stock P/E of Entero Healthcare Solutions Ltd?
The Stock P/E of Entero Healthcare Solutions Ltd is 39.2.
What is the Book Value of Entero Healthcare Solutions Ltd?
The Book Value of Entero Healthcare Solutions Ltd is 406.
What is the Dividend Yield of Entero Healthcare Solutions Ltd?
The Dividend Yield of Entero Healthcare Solutions Ltd is 0.00 %.
What is the ROCE of Entero Healthcare Solutions Ltd?
The ROCE of Entero Healthcare Solutions Ltd is 8.71 %.
What is the ROE of Entero Healthcare Solutions Ltd?
The ROE of Entero Healthcare Solutions Ltd is 5.63 %.
What is the Face Value of Entero Healthcare Solutions Ltd?
The Face Value of Entero Healthcare Solutions Ltd is 10.0.